Therapy-related acute myeloid leukemia (t-AML), defined as AML arising from prior
cytotoxic, radiation, or immunosuppressive therapy for an unrelated disease, accounts for …

CPX-351 and venetoclax and azacitidine (ven/aza) are both indicated as initial therapy for
acute myeloid leukemia (AML) in older adults. In the absence of prospective randomized …

Simple Summary Assessment of measurable residual disease (MRD) identifies small
numbers of acute myeloid leukemia (AML) cells that may remain after initiating treatment …

The benefit of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients
with acute myeloid leukemia (AML) aged> 60 years remains a matter of debate, notably …

Simple Summary Acute myeloid leukemia (AML) is an aggressive cancer of the
hematopoietic system. At present, we know that AML is heterogeneous and varies from one …

Simple Summary Secondary AML (s-AML) including therapy-related acute myeloid leukemia
(t-AML) and acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) …

Simple Summary Relapse as the most common reason for treatment failure after allogeneic
hematopoietic stem-cell transplantation (allo-SCT) in myeloid neoplasms usually occurs …

Acute myeloid leukemia (AML) is a heterogeneous disease with a wide variety of clinical
presentations, morphological features, and immunophenotypes. The diagnostic approaches …

The liposomal formulation of cytarabine/daunorubicin (CPX-351) has been shown to
improve overall survival (OS) in older (60-75 years of age) patients with newly diagnosed …

Purpose CPX-351 is dual-drug liposomal encapsulation of daunorubicin and cytarabine at a
fixed synergistic 1: 5 molar ratio. This study determined current real-world use of CPX-351 …